Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long non-coding RNAs (lncRNAs) are aberrantly expressed in many diseases including cancer. LncRNA
CASC2
(cancer susceptibility candidate 2) has been characterized as a tumor suppressor in endometrial cancer and colorectal cancer. However, the role and function of
CASC2
in human gliomas remain unknown. In this study, we confirmed that
CASC2
was lowly expressed in
glioma
tissues as well as in U251 and U87
glioma
cell lines. Overexpression of
CASC2
inhibited the malignancy of
glioma
cells, including proliferation, migration, and invasion, and promoted cell apoptosis. MicroRNA-21 (miR-21) has been reported to be overexpressed in human
glioma
tissues and cell lines, which is responsible for the malignant progression of
glioma
. We found that up-regulated
CASC2
decreased the expression of miR-21 significantly and there is a reciprocal repression between
CASC2
and miR-21 in an Argonaute2-dependent manner. Furthermore, bioinformatics, luciferase reporter assays and pull-down assay confirmed that miR-21 binds to
CASC2
in a sequence-specific manner. Introduction of miR-21 largely abrogated
CASC2
-mediated inhibition of
glioma
cell proliferation, migration, and invasion, and promotion of cell apoptosis. This study demonstrated that
CASC2
plays a tumor suppressive role in
glioma
via negative regulation of miR-21, which may be a novel therapeutic target for treating gliomas.
...
PMID:Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. 2544 61
Recently long non-coding RNAs (lncRNAs) were highlighted for their regulatory role in tumor biology. The novel human lncRNA cancer susceptibility candidate 2 (
CASC2
) has been characterized as a potential tumor suppressor in several tumor types. However, the roles of
CASC2
and its interplay with
miR-21
in different malignancy grade patient gliomas remain unexplored. Here we screened 99 different malignancy grade astrocytomas for
CASC2
, and
miR-21
gene expression by real-time quantitative polymerase chain reaction (RT-qPCR) in isocitrate dehydrogenase 1 (
IDH1
) and O-6-methylguanine methyltransferase (
MGMT
) assessed gliomas.
CASC2
expression was significantly downregulated in glioblastomas (
p
= 0.0003).
Gliomas
with low
CASC2
expression exhibited a high level of
miR-21
, which was highly associated with the higher
glioma
grade (
p
= 0.0001),
IDH1 wild type
gliomas (
p
< 0.0001), and poor patient survival (
p
< 0.001). Taken together, these observations suggest that
CASC2
acts as a tumor suppressor and potentially as a competing endogenous RNA (ceRNA) for
miR-21,
plays important role in
IDH1 wild type
glioma
pathogenesis and patients' outcomes.
...
PMID:The Role of
CASC2
and
miR-21
Interplay in Glioma Malignancy and Patient Outcome. 3312 Sep 18